Cyclo Therapeutics up on research collaboration for lead drug

Cyclo Therapeutics

24/03/2022 12:39

** Shares of drug developer  CYTH.O  rise 8.4% to $3.09
premarket
    ** Co enters into a research and collaboration agreement
with Wits Commercial Enterprise, a wholly owned subsidiary of
the University of the Witwatersrand, in Johannesburg (https://refini.tv/36qAUGS)
    ** Under terms of agreement, the companies plan to develop
and coordinate projects or activities to further the scientific
advancement of CYTH's lead drug, Trappsol Cyclo
    ** Trappsol Cyclo is currently being tested in a late-stage
study to treat a type of progressive genetic disorder called
Niemann-Pick
    ** CYTH expects to shortly begin mid-stage trials for
Trappsol Cyclo in treating early Alzheimer's Disease 
    ** As of last close, stock had lost ~23.59% this year

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))